H&E Major Pulse "ONCO: R$500mn capital injection reportedly being evalua..."

Research evidence excerpt

H&E Major Pulse "ONCO: R$500mn capital injection reportedly being evalua..."

such as radiotherapy and chemotherapy, as well as invest in additional

medical equipment. The goal is for oncology to deliver 30% revenue growth by

2026, double the company’s overall expected growth of 15%.

Anvisa prepares to regulate the sale of medications on marketplaces: Anvisa is

expected to soon begin discussions on regulating the sale of healthcare

products on marketplaces. The process is set to start once measures related to

the control of raw material imports and the compounding of GLP-1 analogs are

finalized. The discussion is expected to be preceded by a regulatory impact

assessment. While the topic is considered urgent, there is a view that standard

regulatory procedures should be followed

ANS and AbbVie sign discount agreement: ANS and AbbVie have signed a

commitment agreement to offer commercial discounts on Skyrizi, indicated

for the treatment of moderate to severe ulcerative colitis. The agreement was

executed as part of the process for inclusion of the therapy in the ANS

coverage list. The terms establish a minimum discount of 15% off the factory

price for the 600mg version and 7% for the 180mg version of the drug.

Global study shows mixed trends in obesity across countries

SNCR: Anvisa’s New Prescription Control System

Education

Other News

LAUR approves 2026 Long-Term Incentive Plan: Laureate filed a Form S-8 with

the SEC to register up to 8.55 million shares under its newly approved 2026

Long-Term Incentive Plan. The plan is designed to attract, retain, and

incentivize employees and executives through equity-based compensation

(e.g., stock options, restricted stock, and performance awards). The total

registered value is set at maximum US$277mn.

LAUR announces Mr.